ERAGNY-SUR-OISE, France--(BUSINESS WIRE)--Regulatory News:
SAFE ORTHOPAEDICS (Paris:SAFOR) (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, today announces the appointment of François-Henri Reynaud as Chief Financial and Administrative Officer.
François-Henri has 13 years’ experience in finance. For five years, he was initially involved in financing innovative business companies in a financial institution, before overseeing several corporate finance transactions (fund-raising transactions, mergers and acquisitions) as Chief Financial and Administrative Officer of companies in a variety of sectors including medical devices and renewable energies. His most recent appointment was at Global Bioenergies, a listed industrial biology company.
François-Henri Reynaud’s main role will be to handle the Company’s financial and administrative affairs, working closely with the Chief Executive Officer.
François-Henri Reynaud, Safe Orthopaedics’ new Chief Financial and Administrative Officer, commented: “It is a unique opportunity to join Safe Orthopaedics just as the Company has reported an increase in its third-quarter revenues of over 63% year-on-year and is expanding its business worldwide.”
Pierre Dumouchel, Chief Executive Officer and Co-founder of Safe Orthopaedics, added: “Together with his expertise in finance, François-Henri’s appointment as Chief Financial and Administrative Officer brings to the table his experience of establishing and building up international subsidiaries just as Safe Orthopaedics embarks on a new phase of expansion to accelerate its growth and business development”.
Next financial release: full-year 2017 revenues, Monday, January 15, 2018 (after the market closes)
About Safe Orthopaedics
Founded in 2010, Safe Orthopaedics is a French medical technology company that aims to make spinal surgeries safer by using sterile implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpineTM kits are CE-marked and FDA approved. The company is based at Eragny-sur-Oise (Val d’Oise department), and has 34 employees.
For more information, visit: www.SafeOrtho.com